# US 2015/0147390 A1 · Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147390 A1
- Document ID: US20150147390A1
- Status: Published application
- Kind: A1
- Application number: 14/606,923
- Filed: 2015-01-27
- Published: 2015-05-28
- Earliest claimed: 2010-12-23
- Assignees: Rani Therapeutics, LLC
- Applicants: Rani Therapeutics, LLC
- Inventors: Mir Imran
- Web page: https://patentgrep.com/patent/US20150147390A1

## CPC

- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61M 5/00: Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use A61M39/00; containers specially adapted for medical or pharmaceutical purposes A61J1/00)
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61M 31/007: {Injectors for solid bodies, e.g. suppositories}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

## Claims

### Claim 1

A method for delivering Pramlintide to a patient, said method comprising: providing a solid Pramlintide dosage shaped as a tissue penetrating member; penetrating the solid dosage Pramlintide into an intestinal wall after oral ingestion, wherein Pramlintide is released into the blood stream from the solid dosage Pramlintide in the intestinal wall.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Pramlintide released into the blood stream from the solid dosage Pramlintide reaches a Cmax in a shorter time period than a time period to achieve a Cmax for an extravascularly injected dose of Pramlintide.

### Claim 3 (depends on 2)

The method of claim 2, wherein a tmax for the Pramlintide released from the solid dosage Pramlintide is less than about 80% of a tmax for the extravascularly injected dose of Pramlintide.

### Claim 4 (depends on 2)

The method of claim 2, wherein a tmax for the Pramlintide released from the solid dosage Pramlintide is less than about 50% of a tmax for the extravascularly injected dose of Pramlintide.

### Claim 5 (depends on 2)

The method of claim 2, wherein a tmax for the Pramlintide released from the solid dosage Pramlintide is less than about 30% of a tmax for the extravascularly injected dose of Pramlintide.

### Claim 6 (depends on 2)

The method of claim 2, wherein a tmax for the Pramlintide released from the solid dosage Pramlintide is less than about 10% of a tmax for the extravascularly injected dose of Liraglutide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the tissue penetrating member is inserted into a wall of the small intestine.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tissue penetrating member is orally delivered in a swallowable capsule

### Claim 9 (depends on 8)

The method of claim 8, penetrating the solid dosage Pramlintide into the intestinal wall comprises operably coupling the solid dosage Pramlintide to a delivery means having a first configuration wherein the solid dosage Pramlintide is within the capsule and a second configuration wherein the solid dosage Pramlintide is advanced out of the capsule and into the intestinal wall.

### Claim 10 (depends on 9)

The method of claim 9, wherein penetrating the solid dosage Pramlintide into the intestinal wall comprises expanding at least one expandable balloon from the first to the second configuration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the solid dosage Pramlintide comprises a biodegradable material which degrades within the intestinal wall to release Pramlintide into the blood stream.

### Claim 12 (depends on 11)

The method of claim 11, wherein the biodegradable material comprises PGLA, a sugar or maltose.

### Claim 13 (depends on 11)

The method of claim 11, wherein the solid dosage Pramlintide comprises at least one pharmaceutical excipient.

### Claim 14 (depends on 13)

The method of claim 13, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.

### Claim 15 (depends on 14)

The method of claim 14, wherein the binder comprises PEG.

### Claim 16 (depends on 1)

The method of claim 1, wherein a weight percent of Pramlintide in the solid dosage Pramlintide comprises between about 3 to 6%.

### Claim 17 (depends on 1)

The method of claim 1, wherein a dose of pramlintide in the solid dosage Pramlintide is in a range from about 0.1 to 1 mg.

### Claim 18 (depends on 17)

The method of claim 17, wherein the dose of pramlintide is about 0.6 mg.

### Claim 19 (depends on 1)

The method of claim 1, further comprising retaining the solid dosage Pramlintide within the intestinal wall after insertion.

### Claim 20 (depends on 17)

The method of claim 17, wherein retaining comprises anchoring at least one of a barb or an inverse taper shape of the solid dosage Pramlintide in the intestinal tissue.

### Claim 21 (depends on 1)

The method of claim 1, wherein penetrating the solid dosage Pramlintide comprises applying a force to the solid dosage Pramlintide, wherein the solid dosage Pramlintide has sufficient stiffness to be advanced completely into the intestinal wall by such application of force.

### Claim 22 (depends on 1)

The method of claim 1, wherein the solid dosage Pramlintide produces a long-term release of Pramlintide.

### Claim 23 (depends on 1)

The method of claim 1, wherein the Cmax achieved by delivering the solid dosage Pramlintide into the intestinal wall is at least about 10 times greater than the Cmax achieved when the preparation is delivered orally without insertion into the intestinal wall.

### Claim 24

A method for delivering Pramlintide to a patient, said method comprising: providing a Pramlintide dosage within a swallowable capsule having at least one tissue penetrating member having a lumen; delivering the Pramlintide dosage into a wall of the small intestine from the capsule via the tissue penetrating member lumen and an application of force on the Pramlintide dosage, the delivery of the Pramlintide being effectuated responsive to a condition unique to the small intestine, and wherein the Pramlintide is released into the blood stream from the dosage of Pramlintide in the wall of the small intestine.

### Claim 25 (depends on 24)

The method of claim 24, wherein the condition is a pH.

### Claim 26 (depends on 24)

The method of claim 24, wherein the Pramlintide dosage is in solid form.
